Telmisartan Market Size, Share, Outlook, and Analysis, 2018-2026

Prevalence of high blood pressures, is increasing globally attributed to rising geriatric population, chronic disorders such as diabetes, and changing lifestyles which in turn is expected to increase the demand for telmisartan in global market. According to Blood Pressure UK, 2017 update, high blood pressure is the leading cause of heart disease and stroke, killing around 7.5 million people worldwide every year. In 1975, 594 million people were suffering from high blood pressure which increased to 1.1 billion in 2015 and is thought to be due to population growth and an aging population.

Advertisements
your ads here

Request Sample of Report: https://www.coherentmarketinsights.com/insight/request-sample/2524

Furthermore, increasing approvals for Abbreviated new Drug Application (ANDA) for manufacturing of generic telmisartan tablets is propelling growth of telmisartan in the global market. For instance, in July 2014, Glenmark Generics Inc., USA—a subsidiary of Glenmark Generics Limited—received ANDA approval from the U.S. Food and Drug Administration (USFDA) for telmisartan tablets.

Telmisartan is a prescription medication often prescribed to relax and widen blood vessels in persons with high blood pressure. Telmisartan belongs to a group of drugs called angiotensin II receptor blockers (ARBs). Telmisartan may be used alone or in combination with other medications such as hydrochlorothiazide for treatment of high blood pressure.

Increasing awareness regarding hypertension and its management by organizing global campaigns are expected to drive growth of the market. For instance, in May 2017, Argentinian Society of Hypertension (SAHA) participated in global campaigns named May Measurement Month and World Hypertension Day for creating awareness among population related to blood pressure and their management.

Key players are focused on development and launch of new generic product to maximize access to end users for their product in less cost, in turn gaining market share in telmisartan market. For instance, in June 2017, Solco Healthcare, announced its FDA approval for Telmisartan tablets, 20mg, 40mg, and 80mg, which are AB-rated equivalents to Micardis by Boehringer Ingelheim. Solco Healthcare will market Telmisartan tablets in 30 count bottles for all three strengths.

Get PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/2524

Moreover, increasing government initiatives for hypertension management is expected to drive growth of the global Telmisartan market. For instance, in December 2017, the Secretary, Ministry of Health and Family Welfare (MOHFW) and Secretary, Department of Health Research (DHR) and Director General, Indian Council of Medical Research (ICMR) launched, the India Hypertension Management Initiative (IHMI). The IHMI aims to reduce disability and death related to cardiovascular disease (CVD), by improving control over high blood pressure (hypertension), reducing salt consumption from food, and eliminating artificial trans-fats, which are leading risk factors for developing CVD.

Key players operating in the Telmisartan market include Medtronic Plc., General Electric Company, C. R. Bard, Inc., ConvaTec Group plc. Smith Medical, Inc., KindWell Medical Equipment Co.,Ltd, Royax, Fuji Systems Corp., Teleflex Incorporated., Neurovision Medical Products, and Intersurgical GmbH

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com